Immunology / Systemic Lupus Erythematosus
Indication
Systemic Lupus Erythematosus
Assets addressing this indication.
Total attributable cost
$4.5B
$22,000/patient
Drug spend
$1.6B
$7,600/patient
35% of total cost is drugs
All adult and pediatric SLE; 2018 population estimate · US